Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

842
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
842
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Massive pancarditis-autopsy report].

Pathologie (Heidelberg, Germany)·2023
Same author

[Use of central anticholinergics in 2022].

Revue medicale de Liege·2022
Same author

[Unusual location of a common dermatosis].

Dermatologie (Heidelberg, Germany)·2022
Same author

Telemedical care of men with androgenetic alopecia demonstrates improved access to care and patient benefit.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

[Multiple sclerosis : a neurological dysimmune inflammatory disease].

Revue medicale de Liege·2022
Same author

The Complex Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis.

Psychologica Belgica·2022
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K

[Multiple sclerosis : therapy update].

D Dive1, S Dauby1, E Lommers1

  • 1Unité de Neuroimmunologie, CHU Liège, Belgique.

Revue Medicale De Liege
|June 5, 2020
PubMed
Summary
This summary is machine-generated.

Recent therapeutic advancements have significantly improved care for multiple sclerosis (MS), a disabling condition in young adults. Early intervention in specialized centers now frequently achieves no evidence of disease activity (NEDA), transforming patient outcomes.

Keywords:
DiseaseMultiple SclerosisUpdateMonoclonal antibodiesmodifying therapy

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.6K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

17.2K

Related Experiment Videos

Last Updated: Dec 19, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.6K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

17.2K

Area of Science:

  • Neurology
  • Immunology
  • Clinical Therapeutics

Background:

  • Multiple sclerosis (MS) remains a significant cause of disability in young adults.
  • Therapeutic strategies for MS have seen considerable recent advancements.
  • Improved understanding and patient care are transforming MS management.

Purpose of the Study:

  • To highlight recent therapeutic progress in multiple sclerosis.
  • To emphasize the importance of early treatment and specialized care.
  • To discuss the achievement of no evidence of disease activity (NEDA) as a treatment goal.

Main Methods:

  • Review of recent advancements in multiple sclerosis therapeutics.
  • Analysis of the impact of new drugs and treatment rationales.
  • Evaluation of multidisciplinary care models in specialized units.

Main Results:

  • Therapeutic progress has considerably improved knowledge and patient care in MS.
  • Early treatment in specialized centers is a key factor for success.
  • Clinical and neuroradiological no evidence of disease activity (NEDA) is increasingly achievable.
  • Patient follow-up and evolution have significantly improved with greater efficacy.

Conclusions:

  • Recent therapeutic progress has substantially enhanced multiple sclerosis management.
  • Achieving no evidence of disease activity (NEDA) is a more attainable goal.
  • Specialized, multidisciplinary care and early intervention are crucial for improved patient outcomes.